← The Wire
TVTXNasdaq
Travere Therapeutics, Inc.
Pharmaceutical Preparations · CA · CIK 1438533
Travere Therapeutics develops and delivers life-changing therapies for rare kidney and metabolic diseases
red 8-K · 90d⚡ Elevated coverage
$4.84B
Market cap
$58.30
Last close
-0.9%
1D
+5.8%
5D
1.4M
Volume
Price · last 39 sessions+29.8%
May 4L $42.26 · H $59.03Jun 29
267
Total filings
Jun 16, 2026
Last filing
12/31
Fiscal year end
8-KExecutive ChangeJun 16, 20268-KMaterial AgreementJun 2, 20268-KExecutive Change · Shareholder VoteMay 21, 20268-KMaterial Agreement · New Debt / ObligationMay 11, 2026424B5424B5May 7, 2026424B5424B5May 5, 202610-Q10-QMay 4, 20268-KResults of OperationsMay 4, 20268-KCompany UpdateApr 14, 2026DEFA14ADEFA14AApr 6, 2026DEF 14ADEF 14AApr 6, 202610-K10-KFeb 19, 20268-KResults of OperationsFeb 19, 20268-KCompany UpdateJan 13, 20268-KResults of OperationsJan 12, 202610-Q10-QOct 30, 20258-KResults of OperationsOct 30, 20258-KCompany UpdateSep 10, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KExecutive Change · Shareholder VoteMay 16, 20258-KCompany UpdateMay 15, 20258-K/AResults of OperationsMay 1, 202510-Q10-QMay 1, 20258-KAcquisition / DispositionMay 1, 20258-KCompany UpdateApr 30, 2025DEFA14ADEFA14AApr 1, 2025DEF 14ADEF 14AApr 1, 20258-KCompany UpdateMar 17, 202510-K10-KFeb 21, 20258-KResults of OperationsFeb 20, 20258-KCompany UpdateFeb 11, 20258-KResults of OperationsJan 13, 2025SC 13GTRAVERE THERAPEUTICS, INC.Nov 14, 20248-KCompany UpdateNov 8, 2024424B5424B5Nov 8, 2024424B5424B5Nov 7, 2024424B5424B5Oct 31, 202410-Q10-QOct 31, 20248-KResults of OperationsOct 31, 20248-KCompany UpdateSep 26, 20248-KCompany UpdateSep 6, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Shareholder VoteMay 13, 202410-Q10-QMay 6, 20248-KResults of OperationsMay 6, 2024SC 13GSC 13GMay 1, 20248-KCompany UpdateApr 24, 2024DEFA14ADEFA14AMar 27, 2024DEF 14ADEF 14AMar 27, 20248-KCompany UpdateFeb 23, 202410-K10-KFeb 20, 20248-KResults of OperationsFeb 15, 2024SC 13GMS INITIALFeb 9, 20248-KResults of OperationsJan 8, 20248-KExit / Disposal Costs · Company UpdateDec 4, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KCompany UpdateSep 21, 20238-K/ACompany UpdateSep 7, 20238-KAcquisition / DispositionSep 5, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KMaterial AgreementJul 17, 20238-KCompany UpdateMay 31, 20238-KExecutive Change · Shareholder VoteMay 22, 202310-Q10-QMay 4, 20238-KResults of OperationsMay 4, 20238-KCompany UpdateMay 1, 2023DEF 14ADEF 14AApr 13, 20238-KAuditor ChangeApr 12, 2023SC 13GTRAVERE THERAPEUTICS, INC.Mar 13, 20238-KCompany UpdateMar 1, 2023424B5424B5Mar 1, 2023424B5424B5Feb 27, 202310-K10-KFeb 23, 20238-KResults of OperationsFeb 23, 20238-KCompany UpdateFeb 17, 2023SC 13GSC 13GFeb 6, 2023
Insider Activity
In the 90 days to Mar 16, 2026: 7 sold $13.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 10,000 | $28.09 | $281K |
| Feb 20, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 60,000 | $30.10 | $1.8M |
| Feb 17, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 5,679 | $27.50 | $156K |
| Feb 17, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 4,321 | $28.26 | $122K |
| Feb 4, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 2,485 | $32.07 | $80K |
| Feb 4, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sell | 1,635 | $32.14 | $53K |
| Feb 4, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Sell | 1,547 | $32.11 | $50K |
| Feb 4, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 509 | $32.74 | $17K |
| Feb 4, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Sell | 232 | $32.85 | $8K |
| Feb 4, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sell | 110 | $32.90 | $4K |
| Feb 3, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 66,452 | $32.06 | $2.1M |
| Feb 3, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 33,635 | $32.70 | $1.1M |
| Feb 3, 2026 | Rote William E.Chief Research Officer | Sell | 12,446 | $32.87 | $409K |
| Feb 3, 2026 | Heerma PeterCHIEF COMMERCIAL OFFICER | Sell | 7,310 | $32.12 | $235K |
| Feb 3, 2026 | Cline Christopher R.CHIEF FINANCIAL OFFICER | Sell | 7,242 | $32.12 | $233K |
| Feb 3, 2026 | Reed Elizabeth EChief Legal Officer and GC | Sell | 7,175 | $32.12 | $230K |
| Feb 3, 2026 | Inrig JulaCHIEF MEDICAL OFFICER | Sell | 6,956 | $32.12 | $223K |
| Feb 3, 2026 | Calvin SandraSVP, CHIEF ACCOUNTING OFFICER | Sell | 4,333 | $32.12 | $139K |
| Jan 27, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 51,865 | $30.10 | $1.6M |
| Jan 23, 2026 | Dube Eric MCHIEF EXECUTIVE OFFICER | Sell | 8,135 | $30.01 | $244K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article.
ReutersTravere licenses Everest's kidney disease drug in deal worth up to $1.14 billion28d agoInvestor's Business DailyTravere, IBD Stock Of The Day, Is On Path To $3 Billion And In A Buy Zone1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance